High Helicobacter pylori Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescents

Página do item simplificado
dc.contributor.authorOgata, Silvio Kazuo [UNIFESP]
dc.contributor.authorOrtiz Godoy, Anita P. [UNIFESP]
dc.contributor.authorSilva Patricio, Francy R. da [UNIFESP]
dc.contributor.authorKawakami, Elisabete [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:31:48Z
dc.date.available2016-01-24T14:31:48Z
dc.date.issued2013-06-01
dc.description.abstractObjective: the aim of the present study was to assess the primary and secondary resistance of Helicobacter pylori strains to clarithromycin, amoxicillin, furazolidone, tetracycline, and metronidazole, the conventional antibiotics presently used in Brazilian children and adolescents.Methods: Seventy-seven consecutive H pylori strains, 71 of 77 strains obtained from patients without previous eradication treatment for H pylori infection, and 6 strains from patients in whom previous eradication treatment had failed.Results: Global rate of resistance was 49.3% (38/77): 40% of strains were resistant to metronidazole, 19.5% to clarithromycin, and 10.4% to amoxicillin. All of the tested H pylori strains were susceptible to furazolidone and tetracycline. Multiple resistance were detected in 18.2% (14/77 patients) of the strains: 6 of 14 (43%) simultaneously resistant to clarithromycin and metronidazole; 5 of 14 (36%) to amoxicillin and metronidazole; 2 of 14 (14%) to amoxicillin, clarithromycin, and metronidazole; and 1 of 14 (7%) to clarithromycin and amoxicillin.Conclusions: the high resistance rate to metronidazole and clarithromycin observed in clinical H pylori isolates can exclude these antimicrobials in empirical eradication treatment in Brazil. Otherwise, furazolidone and tetracycline presented no resistance. Properly assessing the risks and benefits, these 2 antimicrobials and their derivatives could be used in empirical eradication schedules, both associated with amoxicillin, which showed a low resistance rate despite its wide use in pediatric patients.en
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Div Pediat Gastroenterol Hepatol & Nutr, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Dept Clin Pathol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Div Pediat Gastroenterol Hepatol & Nutr, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Dept Clin Pathol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.format.extent645-648
dc.identifierhttp://dx.doi.org/10.1097/MPG.0b013e31828b3669
dc.identifier.citationJournal of Pediatric Gastroenterology and Nutrition. Philadelphia: Lippincott Williams & Wilkins, v. 56, n. 6, p. 645-648, 2013.
dc.identifier.doi10.1097/MPG.0b013e31828b3669
dc.identifier.issn0277-2116
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/36363
dc.identifier.wosWOS:000319559800024
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Pediatric Gastroenterology and Nutrition
dc.rightsAcesso aberto
dc.subjectAmoxicillinen
dc.subjectClarithromycinen
dc.subjectFurazolidoneen
dc.subjectHelicobacter pylorien
dc.subjectMetronidazoleen
dc.subjectResistanceen
dc.subjectSusceptibilityen
dc.subjectTetracyclineen
dc.titleHigh Helicobacter pylori Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescentsen
dc.typeArtigo
Arquivos
Coleções
Em verificação - Geral